iBio’s Chief Legal Officer Buys 25,000 Shares Amid Stock’s 56% YTD Decline, Signaling Executive Confidence
iBio insider buying surge: Banjak Marc’s recent shares hint confidence amid a steep decline—should investors “buy‑the‑dip” or stay cautious?
3 minutes to read